The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma

References

• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311: 1471–1475.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, . Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cancer-associated myeloproliferation: old association, new therapeutic target. Mayo Clin Proc 2010;85:656–663.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Wada DA, Ziesmer SC, . Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009;114:2936–2944.
   PubMed Web of Science ®Google Scholar
• Nardelli B, Belvedere O, Roschke V, . Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198–204.
   PubMed Web of Science ®Google Scholar
• Clear AJ, Lee AM, Calaminici M, . Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163 + macrophages within the immediate sprouting microenvironment. Blood 2010;115:5053–5056.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, . Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875–885.
   PubMed Web of Science ®Google Scholar
• Cox CJ, Habermann TM, Payne BA, . Evaluation of the Coulter Counter model S-Plus IV. Am J Clin Pathol 1985;84:297–306.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34:187–202.
   Google Scholar
• Nagaraj S, Collazo M, Corzo CA, . Regulatory myeloid suppressor cells in health and disease. Cancer Res 2009;69:7503–7506.
   PubMedGoogle Scholar
• Schmidt H, Bastholt L, Geertsen P, . Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005;93:273–278.
   PubMed Web of Science ®Google Scholar
• Schmidt H, Suciu S, Punt CJ, . Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J Clin Oncol 2007;25:1562–1569.
   PubMed Web of Science ®Google Scholar
• Paesmans M, Sculier JP, Lecomte J, . Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 2000;89:523–533.
   PubMed Web of Science ®Google Scholar
• Michael M, Goldstein D, Clarke SJ, . Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer 2006;6:297–304.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological malignancies—a possible tumor-associated marker. J Cancer Res Clin Oncol 1986;111:54–58.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Garcia JA, Elson P, . Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110:543–550.
   PubMed Web of Science ®Google Scholar
• Donskov F, von der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006;24:1997–2005.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, . The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 2011;25:1502–1509.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, . Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140–147.
   PubMed Web of Science ®Google Scholar
• Gribben JG. How I treat indolent lymphoma. Blood 2007;109: 4617–4626.
   PubMed Web of Science ®Google Scholar
• Gribben JG. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr Opin Oncol 2010;22:424–430.
   PubMed Web of Science ®Google Scholar
• Buechler C, Ritter M, Orso E, . Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 2000;67:97–103.
   PubMed Web of Science ®Google Scholar
• Farinha P, Masoudi H, Skinnider BF, . Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169–2174.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, . Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006;24:5350–5357.
   PubMed Web of Science ®Google Scholar
• Glas AM, Knoops L, Delahaye L, . Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007;25:390–398.
   PubMed Web of Science ®Google Scholar
• de Jong D, Koster A, Hagenbeek A, . Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009;94:70–77.
   PubMed Web of Science ®Google Scholar
• Canioni D, Salles G, Mounier N, . High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008; 26:440–446.
   PubMed Web of Science ®Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Nyman H, . A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784–5789.
   PubMed Web of Science ®Google Scholar
• Leidi M, Gotti E, Bologna L, . M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 2009;182:4415–4422.
   PubMed Web of Science ®Google Scholar
• Cittera E, Leidi M, Buracchi C, . The CCL3 family of chemokines and innate immunity cooperate in vivo in the eradication of an established lymphoma xenograft by rituximab. J Immunol 2007;178:6616–6623.
   PubMed Web of Science ®Google Scholar
• Lefebvre ML, Krause SW, Salcedo M, . Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 2006; 29:388–397.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Shivakumar L, Ansell S. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Clin Lymphoma Myeloma 2006;7:106–108.
   PubMedGoogle Scholar
• Novak AJ, Grote DM, Stenson M, . Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 2004;104:2247–2253.
   PubMed Web of Science ®Google Scholar
• Oki Y, Georgakis GV, Migone TS, . Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma. Haematologica 2007;92:269–270.
   PubMed Web of Science ®Google Scholar
• Tecchio C, Nadali G, Scapini P, . High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 2007;137:553–559.
   PubMed Web of Science ®Google Scholar